|
|
|
|
| Symbol(s): |
FOLD |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
Amicus Therapeutics has a current Overall Rating of D (Negative). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| Amicus Therapeutics has a current Overall Rating of D (Negative). Appreciation potential (48) is neutral; Power Rating (10) is very low. Relative to the S&P 500 Composite, Amicus Therapeutics Inc has moderate Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. FOLD is of low investment quality. Amicus Therapeutics' current technical position is very weak. Amicus Therapeutics' Power Rating is 10. However, earnings estimate behavior for FOLD has been...
| | |
|
|
